Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company engaged in the development of novel NNR Therapeutics™ for the treatment of diseases and disorders of the nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, which we refer to as NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. Based on years of focused research in the NNR area, we believe that compounds that interact selectively with specific NNR subtypes have the potential to achieve positive medical effects by modulating their activity. We have built an extensive patent estate covering the structure or therapeutic use of small molecules designed to regulate activity in the body by selectively affecting specific NNR subtypes. We have multiple clinical-stage product candidates in areas in which we believe there are significant medical need and commercial potential, as well as an ongoing collaboration with AstraZeneca. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.1 |
| Quarterly EPS Est: | -0.37 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
2.5 |
Data is provided by Zacks Investment Research
